C-NBUCCambrian Bio
aging biology, mTORC1 inhibition, AMPK activation
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-NBUC
C-NBUCC-NBUCaging biology, mTORC1 inhibition, AMPK activation
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Longevity science has finally reached broad consensus, here's what comes next. Become a Cure member → wewillcure.com/membership James Peyer, CEO of Cambrian Biopharma, has spent two decades in longevity science. In this clip, he breaks down why the first-ever scientific consensus on aging is also an open door for bad actors — and why the only defense is medicines that are proven to work, beyond any doubt. Filmed at Cure Studios, New York City Subscribe to Cure's YouTube: https://www.youtube.com/@wewillcure?sub_confirmation=1 Cure is the membership community and media engine for healthcare founders, investors, and operators building the next generation of health companies. Website: wewillcure.com LinkedIn: www.linkedin.com/company/curenyc/
Can aging biology become medicine? Episode 21 of Decoding Longevity features James Peyer (CEO, Cambrian Biopharma) in conversation with Raghav Sehgal and Macsue Jacques. Topics include geroscience drug development, exercise mimetics, AMPK & mTOR pathways, and the future of preventive medicine. #longevity #agingresearch #preventivemedicine
Beginning in Biotech: Insights from Insiders | AFAR Webinar (October 3, 2023) Today more than ever, biomedical researchers have more opportunities to bring to market new therapeutics and interventions to extend healthspan. In this webinar, AFAR Grantee Kristen Fortney of BioAge, Jim Mellon of Juvenescence, James Peyer of Cambrian Biopharma, and moderator Sergey Young of Longevity Vision Fund reveal what they look for in scientific collaborators and proposals, share tips on investor relations and business planning, and field your questions on moving research from the labs into our lives. Learn more about aging research: https://www.afar.org/ Follow AFAR on social media: Facebook: American Federation for Aging Research LinkedIn: American Federation for Aging Research
In this wide-ranging fireside chat, Bio Protocol founder Paul Kohlhaas sits down with biotech and crypto investor Christian Angermayer, founder of the Apeiron Investment Group and early backer of atai Life Sciences, Cambrian Bio, and Rejuveron. They explore the intersection of decentralized science (DeSci), longevity, psychedelics, AI, and personal freedom. Christian shares stories from building billion-dollar biotech ventures, discusses the failures of the traditional research system, and calls for radical honesty and autonomy in how we enhance the human experience. From terminal patient trials to self-governed biohacking and regulatory overhauls, this is a bold blueprint for the future of health, medicine, and personal agency.
OpenAI’s new model, GPT-4b micro, is trained with Retro Biosciences to extend human life by 10 years. Sam Altman has been working with Retro on the research for almost a year. What does the micro model do? It tries to re-engineer proteins (Yamanaka factors). This set of proteins can turn our skin cells into younger stem cells, which can be a game changer when building human organs and providing replacement cells. Retro aspires to add 10 years to the human lifespan - starting with Autophagy Enhancement, HSC Reprogramming, and Microglia therapeutics. Other billionaires have joined the longevity race. Jeff Bezos and others are said to have committed $3 billion in funding the Altos Labs, a secretive San Diego-based longevity laboratory. Cambrian Bio Chairman Christian Angermayer has been focusing on developing different anti-aging (slowing aging) treatments and pills, including one to keep a woman’s ovaries younger to prolong the fertility window. If you liked this video, subscrib
Christian Angermayer is seemingly behind every flashy investment of the last decade. With boundless bravado and a roster of famous friends—including Peter Thiel, Uma Thurman, and the president of Rwanda—the German billionaire is getting ready to launch the Enhanced Games, a 21st-century Olympics on steroids—literally. When Angermayer’s friend Aron D’Souza, an entrepreneur and the lawyer who worked with Peter Thiel to take down Gawker Media, mentioned he wanted to disrupt the Olympics by launching a major sporting event that allows athletes to dope with performance-enhancing drugs (under a doctor’s supervision), Angermayer thought the idea was brilliant. In 2018, Angermayer started his own psychedelics firm, ATAI Life Sciences, which he took public on the Nasdaq in 2021. ATAI is conducting clinical trials on a suite of psychedelics, from DMT to ibogaine to MDMA. Somewhere along the line, he also got into Bitcoin. He still owns about 1,000 of them, worth about $58 million at the curre
Like a lot of successful entrepreneurs, James Peyer is a bit of an outlier. He thinks about something differently: Aging. To James, aging is a curable illness, something to be treated or prevented. He sits down with Jessi for a conversation on what led him to create Cambrian Biopharma, and why unorthodox ideas are so critical to the development of society and culture. Jessi Hempel, host - https://www.linkedin.com/in/jessihempel/ James Peyer, guest - https://www.linkedin.com/in/jamespeyer/ Jessi's article: https://lnkd.in/geGKMjn4 Subscribe to Hello Monday on LinkedIn: https://lnkd.in/gbUA3Yu Subscribe to our channel: https://www.youtube.com/channel/UCAcR...
NewYorkBIO's breakfast series has gone virtual! Providing engaging speakers on innovation, clinical development, patient engagement and more cutting topics across the biopharmaceutical industry. These events are held live every Tuesday morning at 9AM with open registration for all interested participants. Learn more about our organization at www.newyorkbio.org and follow us on Twitter @NewYorkBIO
Talk Title: Cambrian Bio - Creating longevity drugs at scale James Peyer, CEO and Co-founder of Cambrian Biopharma, presents at Investing in the Age of Longevity 2021. In his talk, James explores the state of the longevity industry and its impact on medicines over the next decade. Explaining the overall trend that the longevity field has recognised, James showcases Cambridge Biopharma's focus on new medicines that target the causes of aging and aging-related diseases. Download the presentation slides: https://bit.ly/3nYFHFp Investing in the Age of Longevity 2021 was held in London on 17 November 2021. The one-day masterclass brought together scientists and business leaders at the cutting edge of the field, who shared the inside track on the latest aging-related discoveries and investment opportunities. Download the event programme: https://bit.ly/3lc0Z0j Find out more about Master Investor: https://www.masterinvestor.co.uk
A Metabesity conference session answering the questions: Are companies entering healthy longevity space? What new business models of commercializing healthy longevity are emerging? How are investors reacting to developments? Moderators: Joe Cook, Jr., Executive Chairman and President of NuSirt Biopharma; former Chairman and CEO of Amylin, USA Dennis Purcell, Founder and Senior Advisor of Aisling Capital, USA Ed Saltzman, Executive Chairman, Cello Health BioConsulting, USA Speakers: Philipp Gut, MD, Department Head at Nestlé Institute of Health Sciences, Nestlé Research, Switzerland Roman Kalista, MD, Co-founder and CEO of RxDiet, USA Jerry McLaughlin, MBA, CEO and Board Member of Life Biosciences, Inc., USA Casey Means, MD, Chief Medical Officer and Co-founder of Levels Health, USA James Peyer, PhD, Founder and CEO of Cambrian BioPharma, USA Pietro Antonio Tataranni, MD, Chief Medical Officer and Senior Vice President of Life Sciences at PepsiCo, USA
Foresight Biotech & Health Extension Meeting sponsored by 100 Plus Capital 2021 program & apply to join: https://foresight.org/biotech-health-extension-program/ Lecture notes: https://foresight.org/salon/james-peyer-cambrian-bio-how-to-fund-and-build-geroprotectors/ James Peyer, Cambrian Bio | How to Fund and Build Geroprotectors James Peyer is the Chief Executive Officer and Co-Founder of Cambrian Biopharma. He also serves as the Chairman of the Board of Sensei Biotherapeutics and board and executive roles across Cambrian’s pipeline. He has spent his entire life dedicated to the mission of finding ways of preventing people from getting diseases like cancer and Alzheimer’s instead of waiting for people to get sick. James was previously Founder and Managing Partner at Apollo Ventures, the first global longevity-focused venture capital firm, investing across the US and Europe. Prior to Apollo, James was a biotech R&D specialist at the New York office of McKinsey & Company, serving majo
This is an episode of The Pomp Podcast with host Anthony "Pomp" Pompliano and guest, James Peyer, PhD the Founder and CEO of Cambrian Biopharma. A Distributed Drug Discovery Company developing therapeutics targeting the biology of aging. Cambrian builds, finances, and manages a pipeline of therapeutics. In this conversation, we discuss ---------- Use PrimeXBT - an award winning trading platform where users can trade Bitcoin and other top cryptocurrencies with leverage. They offer one of the best commissions structures in the industry as well as tight spreads on all Bitcoin trades. It also has some great features, including a copy trading module and more. Register with the link below and use promo code "Pomp" to get a 50% deposit bonus: http://u.primexbt.com/pomp ----------- Pomp writes a daily letter to over 50,000 investors about business, technology, and finance. He breaks down complex topics into easy to understand language while sharing opinions on various aspects of each indu